Literature DB >> 17245718

IRES complexity before IFN-alpha treatment and evolution of the viral load at the early stage of treatment in peripheral blood mononuclear cells from chronic hepatitis C patients.

M A Thélu1, V Leroy, M Ramzan, T Dufeu-Duchesne, P Marche, J P Zarski.   

Abstract

At the early stage of treatment, IFN alpha-2a induces inhibition of HCV replication. The viral load reflects mainly the degradation rate of the viruses. However, differences in the behavior of the viral population depend on changes, which occurred in the HCV-IRES genome. In this study, cloning and sequencing strategies permitted the generation of a large number of IRES sequences from the PBMCs of 18 patients (5 women, 13 men) with chronic hepatitis C. The HCV IRES appeared to be highly conserved structurally. However, some variability was found between the different isolates obtained: 467 substitutions with a median of 7 variants/patients. No relationship was observed between pre-treatment IRES complexity and the viral load at the beginning. However, on review of the evolution of viral load in the PBMCs during the first 3 days of IFN alpha-2a treatment, patients could be classified into two groups: Group 1, in which the viral population continued to replicate and Group 2, in which the viral load decreased significantly (P = 0.01727). Positioning of the mutations on the predicted IRES secondary structure showed that the distribution of the mutations and their apparition frequency were different between the two groups. At the early stage of treatment, IFN alpha-2a was efficient in reducing the viral replication in a significant number of patients; mechanisms of response might affect the virus directly. However, pre-treatment genomic variations observed in the 5'NCR of HCV were not a parameter of a later response to antiviral therapy in chronic hepatitis C patients. (244)

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17245718     DOI: 10.1002/jmv.20792

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

1.  Positional effect of mutations in 5'UTR of hepatitis C virus 4a on patients' response to therapy.

Authors:  Mostafa-K El Awady; Hassan-M Azzazy; Ahmed-M Fahmy; Sherif-M Shawky; Noha-G Badreldin; Samar-S Yossef; Moataza-H Omran; Abdel-Rahman-N Zekri; Said-A Goueli
Journal:  World J Gastroenterol       Date:  2009-03-28       Impact factor: 5.742

2.  Analysis of genotype 1b hepatitis C virus IRES in serum and peripheral blood mononuclear cells in patients treated with interferon and ribavirin.

Authors:  Iwona Bukowska-Ośko; Kamila Caraballo Cortés; Agnieszka Pawełczyk; Rafał Płoski; Maria Fic; Karol Perlejewski; Urszula Demkow; Hanna Berak; Andrzej Horban; Tomasz Laskus; Marek Radkowski
Journal:  Biomed Res Int       Date:  2014-07-03       Impact factor: 3.411

3.  Characterization of Hepatitis C Virus IRES Quasispecies - From the Individual to the Pool.

Authors:  Václav Vopálenský; Anas Khawaja; Luděk Rožnovský; Jakub Mrázek; Tomáš Mašek; Martin Pospíšek
Journal:  Front Microbiol       Date:  2018-04-24       Impact factor: 5.640

Review 4.  Establishment of chronic hepatitis C virus infection: translational evasion of oxidative defence.

Authors:  Shiu-Wan Chan
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.